Related Experiment Videos
[Clinical evaluation of basic fetoprotein in bladder cancer]
T Ichikawa1, Y Nakayama, D Yamada
1Department of Urology, Hiroshima City Hospital.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology
|August 31, 2000
Summary
Basic fetoprotein (BFP) shows correlation with bladder cancer tumor size but is not a reliable screening tool alone. Combining BFP with urine cytology improves bladder cancer detection rates.
Area of Science:
- Urology
- Oncology
- Biochemistry
Background:
- Early diagnosis of bladder cancer is crucial for effective treatment and surgical outcomes.
- Basic fetoprotein (BFP) is a potential biomarker for transitional cell carcinoma detection.
Purpose of the Study:
- To investigate the correlation between urine BFP levels and bladder cancer grade or stage.
- To assess BFP's utility as a biochemical marker for bladder cancer.
Main Methods:
- 66 patients with suspected or confirmed bladder cancer provided urine samples.
- Samples were analyzed for BFP (latex immunoagglutination), urine cytology, and routine urinalysis.
- All patients underwent bladder biopsy for definitive diagnosis.
Main Results:
- BFP sensitivity was 38.9%, cytology 48.1%; specificity was 58.3% (BFP) and 75.0% (cytology).
- Detection rates for invasive bladder cancer were higher with BFP (75%) and cytology (100%) than superficial cancer.
- A significant correlation was found between BFP levels and tumor size (r = 0.695, p < 0.0001).
Conclusions:
- BFP combined with urine cytology enhances bladder cancer detection.
- BFP alone is insufficient for bladder cancer screening.